The Burst
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Ivy
4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read MoreThe Daily
Stock market today: Dow slips as S&P 500, Nasdaq trim gains to hover near latest records
Netflix (NFLX) shares are faltering in premarket trading, despite “solid” second quarter earnings.
The streamer delivered beats on both profit and sales, and upped its full-year revenue guidance in its report late Thursday.
Some on Wall Street had flagged Netflix’s lofty valuation going into the print,